
## George D Dangas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10422432/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stent Technology Reaches Maturity?. JACC: Cardiovascular Interventions, 2020, 13, 2879-2881.	1.1	1
2	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	1.4	17
3	Coronary Artery Stenting. Contemporary Cardiology, 2019, , 273-290.	0.0	0
4	Antithrombotic Treatment after Transcatheter Heart Valves Implant. Seminars in Thrombosis and Hemostasis, 2018, 44, 038-045.	1.5	22
5	Left Main PCI With DES Versus CABG. Journal of the American College of Cardiology, 2018, 72, 2823-2825.	1.2	0
6	The quest for the optimal treatment for inâ€stent restenosis. Catheterization and Cardiovascular Interventions, 2018, 92, 300-301.	0.7	1
7	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. Journal of the American College of Cardiology, 2017, 69, 3055-3066.	1.2	117
8	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing) Tj ETQqO of Cardiology, 2017, 119, 1710-1716.	0 8.rgBT /	Oyerlock 10
9	Bioresorbable Vascular Scaffolds inÂWomen. JACC: Cardiovascular Interventions, 2017, 10, 1891-1893.	1.1	1
10	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	3.0	25
11	Classification and patterns of bifurcation in-stent restenosis (BISR) in the second generation drug eluting stent era. Hellenic Journal of Cardiology, 2017, 58, 167-168.	0.4	1
12	Resistant inâ€stent restenosis in the drug eluting stent era. Catheterization and Cardiovascular Interventions, 2016, 88, 777-785.	0.7	26
13	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	1.1	51
14	Correlates and Impact of Coronary ArteryÂCalcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	1.1	32
15	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	0.7	6
16	Prediction of 1â€year mortality and impact of bivalirudin therapy according to level of baseline risk: A patientâ€level pooled analysis from three randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 391-400.	0.7	8
17	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment– Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	4

18 Hemostasis for Cardiac Catheterization. , 2015, , 2055-2070.

GEORGE D DANGAS

#	Article	IF	CITATIONS
19	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	1.0	49
20	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	1.1	34
21	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2014, 114, 1339-1346.	0.7	30
22	Composite Outcomes in Coronary Bypass Surgery Versus Percutaneous Intervention. Annals of Thoracic Surgery, 2014, 97, 1983-1990.	0.7	9
23	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	1.0	6
24	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. Interventional Cardiology Clinics, 2013, 2, 515-525.	0.2	0
25	The Optimal Duration of Dual Combination Antiplatelet Therapy After Stent Implantation and Perioperative Management Issues. Interventional Cardiology Clinics, 2013, 2, 585-594.	0.2	0
26	Comparative Effectiveness of Revascularization Strategies. New England Journal of Medicine, 2012, 366, 1467-1476.	13.9	521
27	Inâ€stent restenosis of bifurcation lesions: Experience with drugâ€eluting balloons. Catheterization and Cardiovascular Interventions, 2012, 79, 397-398.	0.7	1
28	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	1.0	14
29	Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 974-981.	1.1	106
30	Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal, 2011, 161, 298-306.e1.	1.2	37
31	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	1.1	329
32	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	1.2	663
33	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 55, 2556-2566.	1.2	590
34	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. European Heart Journal, 2009, 30, 1457-1466.	1.0	315
35	Classification and Potential Mechanisms of Intravascular Ultrasound Patterns of Stent Fracture. American Journal of Cardiology, 2009, 103, 818-823.	0.7	90
36	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet, The, 2009, 374, 1149-1159.	6.3	368

#	Article	IF	CITATIONS
37	Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 49, 1362-1368.	1.2	776